Poster #1

Understanding the Role of at-risk cytology and co-testing categories in cervical cancer development: are current tactics in management sufficient?

Presenting Author: Caroline Doyle, BS

Poster #2

Clinical characteristics of patients with cervical cancer undergoing fertility-sparing surgery with cervical excision and lymph node evaluation

Presenting Author: Ashley Zhang, BS

Poster #3

Predicting final pathologic diagnosis by cervical excision margins and endocervical curettage

Presenting Author: Ryan Woodson, MD

Poster #4

Survival in HPV and non-HPV associated invasive cervical cancer: outcomes in a large, integrated healthcare system

Presenting Author: Gracie Williams, MD

Poster #5

The relationship between history of sexual assault and cervical cancer: A meta-analysis

Presenting Author: Kyra Hunsberger, BA

Poster #6

Characterization of Patients with Recurrent and Persistent Cervical Cancer after Chemoradiation Therapy: A Retrospective Chart Review

Presenting Author: Lauren Quinto, MD

Poster #7

Association of Time to Surgery and Rates of Endometrial Cancer in Patients with Endometrial Intraepithelial Neoplasia

Presenting Author: Justin Kim, MD

Poster #8

The Clinical Course of Atypical Polypoid Adenomyoma: A Rare Lesion of Ovulatory Dysfunction

Presenting Author: Susan Lang, MD

Poster #9

Surgical complications with and without removal of the uterus during proctectomy following pelvic radiation for colorectal malignancy

Presenting Author: Roshni Ray, MD

Poster #10

Rate of homologous recombination repair gene expression in endometrial cancer patients

Presenting Author: Alexandra Smick, MD

Poster #11

Long-term survival outcomes of robotic-assisted versus traditional laparoscopy for the treatment of stage I endometrial cancer: a National Cancer Database analysis

Presenting Author: Sarah Davidson, MD

Poster #12

Clinical outcomes in non-English-speaking women undergoing cervical cancer treatment

Presenting Author: Laura Potter, BA

Poster #13

Sociodemographic Factors Associated with Distress among a Diverse Gynecologic Oncology Patient Population

Presenting Author: Joe Haydamous, MD

Poster #14

Influence of genetic risk awareness on high grade serous fallopian tube carcinoma diagnoses

Presenting Author: Christine Walsh, MD, MS

Poster #15

A Comparative Study of Ovarian Cancer Family History by Germline Genetic Testing Results

Presenting Author: Rebecca Shin, MD

Poster #16

Incorporation of immunotherapy or biological targeted therapy in primary anti-cancer treatment in gynecologic malignancy

Presenting Author: Matthew Lee, MD

Poster #17

The Utility of a Gastrointestinal Workup in Patients Diagnosed with Borderline and Invasive Ovarian Mucinous Neoplasms

Presenting Author: Lauren Tostrud, MD

Poster #18

Real-world outcomes of neoadjuvant chemotherapy for ovarian cancer: What happens to patients who never undergo surgery?

Presenting Author: Kelly Bruce, MD

Poster #19

Mucinous ovarian neoplasm – Outcomes of a rare tumor

Presenting Author: Bahareh Hamedi, MD

Poster #20

Establishing a platform for investigating poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor sensitivity in PARP1 knockout cells

Presenting Author: Lindsey Nguy, MD

Poster #21

Pathologic staging discrepancies between stage I and II ovarian and tubal high grade serous carcinoma (HGSC) and impact on survival.

Presenting Author: Kayla Sompel, BS

Poster #22

Non-serous fallopian tube carcinoma: a case series

Presenting Author: Joyce Wang, MD

Poster #23

Cancer care navigation, access to care, and adherence to guideline-based cervical cancer treatment across the 2nd largest US public healthcare system

Presenting Author: Alexandra Smick, MD

Poster #24

Implementation of a Cancer Care Navigation Program in Gynecologic Oncology patients within Safety-net Hospitals

Presenting Author: Daisy Cruz, MD

Poster #25

Non-cancer related emergency department utilization in newly diagnosed endometrial cancer patients

Presenting Author: Chrissy Liu, MD

Poster #26

Let’s talk about sex: Sexual wellbeing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer survivors

Presenting Author: Luis Felipe Falla Zuniga, MD

Poster #27

Palliative care referral and utilization at time of diagnosis in patients with recurrent or advanced stage gynecologic cancers at a single institution

Presenting Author: Breana Hill, MD

Poster #28

Lack of association of routine depression screening results with patient reported needs assessment.

Presenting Author: Alexandra Smick, MD

Poster #29

Outpatient specialty palliative care referral patterns among gynecologic cancer patients

Presenting Author: Rubina Ratnaparkhi, MD

Poster #30

In vitro characterization of patient-derived samples demonstrates the heterogeneity of high grade serous ovarian cancer

Presenting Author: Julia Ritchie, MD

Poster #31

In vitro low passage patient-derived cells demonstrate lack of faithfulness to original sample

Presenting Author: Julia Ritchie, MD

Poster #32

Simplification of Molecular Diagnostics for Point-of-Care HPV Screening

Presenting Author: Jill Roberts, MD

Poster #33

Tumor size predicts overall survival in uterine carcinosarcoma

Presenting Author: Hannah Beer, MD

Poster #34

Characterization and Length of Hospice Admission in Patients with Recurrent Cervical Cancer: A Retrospective Chart Review

Presenting Author: Nicole Spencer, MD

Poster #35

Provider Acceptability of a Biopsy-First Approach to Diagnosis of Endometrial Cancer

Presenting Author: Maya Gross, MD, MPH

Poster #36

Spatial RNA sequencing supports programmed death ligand 2 (PD-L2) as a potential immunotherapy target in high grade serous ovarian carcinoma (HGSOC)

Presenting Author: Elise Yates, MD

4:00 PM – 7:30 PM

Registration Open

Exhibit & Poster Set-Up

6:00 pm – 7:30 pm

Welcome Reception

6:30 AM – 8:00 AM

Breakfast

6:30 PM – 12:00 PM

Registration Open

8:00 AM – 8:10 AM

Welcome & Opening Remarks

8:10 AM -9:15 AM

General Session 1

Moderators: Dr. Amanda Bruegl, Dr. Margaret Liang

• 8:10 am – 8:25 am: Readability assessment of Spanish online patient education materials in gynecologic oncology – presented by Dionna Thomas, BA, University of Kansas School of Medicine
• 8:26 am – 8:41 am: Serum Exosomal E6 and E7 Transcripts in HPV-Positive Cervical Cancer: Potential Biomarkers for Monitoring Disease Progression and Treatment Response – presented by Jill Roberts, MD, University of Miami/Jackson Health System
• 8:42 am – 8:57 am: An Alternative to Excision: Use of Trichloroacetic Acid for Management of High Grade Cervical Dysplasia in Young Women – presented by Sadhvi Batra, MD, Moffitt Cancer Center
• 8:58 am – 9:13 am: Assessing the quality of information on HPV and cervical cancer on TikTok – presented by Andrea Alatorre, BS, University of Arizona College of Medicine Phoenix

9:15 AM – 9:30 AM

Break

9:30 AM – 11:05 AM

General Session 2

Moderators: Dr. Nicole Fleming, Dr. Chirag Shah

• 9:30 am – 9:45 am: Liquid Biopsy Detection of Structural Variant Breakpoints to Monitor Ovarian Cancer Clonal Evolution – presented by Jian Li, MD, PhD, The University of Texas MD Anderson Cancer Center
• 9:46 am – 10:01 am: RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells – presented by Marwa Aljardali, MD, UT Southwestern Medical Center
• 10:02 am – 10:17 am: Impact of somatic TP53 mutation type on benefit from bevacizumab in patients with ovarian cancer, a secondary analysis of NRG/GOG-0218 – presented by Kristina Thiel, PhD, University of Iowa
• 10:18 am – 10:33 am: Does timing matter? Association between time to chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy – presented by Sergei Iugai, MD, The Institute for Cancer Care at Mercy
• 10:34 am – 10:49 am: Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: patient-reported outcomes at diagnosis – presented by Shilpa Mokshagundam, MD, Mayo Clinic
• 10:50 am – 11:05 am: Granulosa Cell Tumor: Impact of Surgical Route and Tumor Rupture on Recurrence – presented by Barbara Goff, MD, University of Washington

11:05 AM – 12:05 PM

Presidential Lecture

AI-Driven Discovery of Dangerous Drug-Drug Interaction – View Presentation
Nicholas Tatonetti, PhD, FACMI, Cedars Sinai Medical Center

Dr. Tatonetti will discuss the application of AI and data mining algorithms to identify unexpected drug-drug interactions (DDIs), a significant yet understudied public health concern. By mining clinical data and utilizing machine learning methods, we discovered and validated two novel DDIs: paroxetine and pravastatin causing hyperglycemia, and ceftriaxone and lansoprazole associated with prolonged QT syndrome. These discoveries were corroborated using electronic health records and validated through laboratory experiments. The integration of informatics methods enables high-throughput and automated discovery processes, highlighting the potential of AI in biomedical research.

12:05 PM – 1:50 PM

Industry Supported Symposium

5:30 PM – 7:00 PM

Networking Event

Activity Overview

The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Advanced Strategies in Ovarian Cancers: Exploring emerging therapies and sequencing strategies in accordance with NCCN Guidelines, an Industry Supported Symposium during the 2024 WAGO Annual Meeting.

This symposium is developed in collaboration between The GOG Foundation, Inc. and ImmunoGen.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate:

• Analyze and apply the National Comprehensive Cancer Network (NCCN) Guidelines to make informed decisions regarding therapies in the competitive ovarian cancer landscape, tailored to individual patient profiles and disease characteristics.
• Evaluate and construct optimal treatment sequences incorporating MIRV, HER2-targeted therapies, and other modalities, leveraging their synergistic potential to maximize treatment efficacy and patient outcomes.
• Assess the role of PARP inhibitors (PARPi) in the management of oncological diseases, including considerations for disease progression and implications for subsequent treatment strategies, enabling participants to develop evidence-based approaches for PARPi progression.
• Demonstrate an understanding of toxicity management, particularly ocular toxicities, and essential testing protocols associated with advanced oncology treatments, equipping participants with the skills necessary to monitor treatment efficacy and mitigate adverse effects effectively.

Moderator

Kathleen Moore, MD

Faculty

Debra Richardson, MD

BJ Rimel, MD

Katherine Fuh, MD, MS, PhD

Agenda

Advanced Strategies in Ovarian Cancers: Exploring emerging therapies and sequencing strategies in accordance with NCCN Guidelines, an Industry Supported Symposium during the 2024 WAGO Annual Meeting

Presented on Thursday, June 13, 2024 | 12:20 PM – 1:50 PM PT

Click here to view the recording.

Welcome & Introduction – View Presentation
All Faculty

Case Presentation 1 – View Presentation

Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA

Optimizing Treatment: NCCN Guidelines in the Ovarian Cancer Landscape – View Presentation
Debra Richardson, MD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA

Case Presentation 2 – View Presentation
Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA

Strategic Sequencing in Oncology: Integrating MIRV, Her2 and Beyond for Optimal Therapeutic Outcomes – View Presentation
Katherine Fuh, MD, MS, PhD, UCSF Health, San Francisco, CA, USA

Case Presentation 3 – View Presentation
Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA

Toxicity Management Fundamentals: Understanding Ocular Complications and Testing in Gynecologic Oncology Treatment – View Presentation
BJ Rimel, MD, Cedar Sinai Medical Center, Samuel Oschin Cancer Center, Los Angeles, CA, USA

PARPi Progression: Navigating Next Steps in Oncology Treatment Strategies
All Faculty

Open Discussion & Closing Comments
All Faculty

6:30 AM – 8:00 AM

Breakfast

6:30 AM – 12:00 PM

Registration Open

7:00 AM – 8:00 AM

Trainee & Early-Career Faculty Session: Optimizing Mentorship in Academic Medicine

Presenters:

• Amanda Bruegl, MD, Oregon Health and Science University
• Isabel Rodriguez, MD, Univeristy of Washington
• Samantha Batman, MD, MPH, The University of Texas MD Anderson Cancer Center
• Susan Lang, MD, Stanford University

7:00 AM – 8:00 AM

WAGO Business Meeting

8:15 AM – 9:20 AM

General Session 3

Moderators: Dr. Tiffany Lai, Dr. Renata Urban

• 8:15 am – 8:30 am: Timely treatment in locally advanced cervical cancer is influenced by social vulnerability index and insurance type – presented by Jessica Liang, UCSF School of Medicine
• 8:31 am – 8:46 am: Fragmentation of care is associated with lower rates of receiving guideline concordant treatment in locally advanced cervical cancer – presented by Audrey Mvemba, UCSF School of Medicine
• 8:47 am – 9:02 am: Predictors of HPV Vaccination in the Postpartum Period for Individuals Aged 18-26 –  presented by Christine Nguyen, MD, Oregon Health & Science University
• 9:03 am – 9:18 am: Factors associated with fertility sparing management and pregnancy in gynecologic precancer and cancer – presented by Christina Lowry, MD, MA, Kaiser San Francisco

9:20 AM – 9:35 AM

Break

9:35 AM – 10:40 AM

General Session 4

Moderators: Dr. Kate Harris, Dr. Carolyn Lefkowits

• 9:35 am – 9:50 am: Patient characteristics associated with aggressive end of life care in California, 2008-2019 – presented by Ross Harrison, MD MPH, Oregon Health & Science University
• 9:51 am – 10:06 am: Assessment of early-death in gynecologic malignancy among the Commission-on-Cancer facilities – presented by Andrew Vallejo, MD, Univeristy of Southern California
• 10:07 am – 10:22 am: Evaluating Caregiver Distress: Caring for Those Who Care for Our Patients – presented by Joe Haydamous, MD, McGovern Medical School
• 10:23 am – 10:38 am: Death with Dignity: Unveiling the Demographics of Medical Aid in Dying (MAID) – presented by Danielle Blemur, MD MPH, Stanford University Obstetrics and Gynecology

10:40 AM – 11:40 AM

Tumor Board

Moderators: Moderators: Dr. Malaika Amneus, Dr. Soledad Jorge, Dr. Margaret Liang

Presenters:

• Eric Rios-Doria, MD, MS, University of Washington
• Ngoc-Anh Le, MD, Banner University Medical Center
• Christine Nguyen, MD, Oregon Health and Science University

11:55 AM – 1:25 PM

Industry Supported Symposium

6:00 PM – 8:00 PM

President’s Reception

Activity Overview

GSK welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Empowering Patients and Providers: A Shared Decision-Making Journey, an Industry Supported Symposium during the 2024 WAGO Annual Meeting.

GSK is proud to partner with experts in the field to present educational materials to support you and your patients.

Course Description

Please join Dr. Fernanda Musa and a patient with a gynecologic cancer as they discuss the burden and unmet needs of gynecologic malignancies, explore the challenges faced by healthcare providers and by patients, and highlight current gaps in disease management of gynecological malignancies. In addition, they will explore patient centricity and shared decision making, including significance of involving patients in their treatment journey, and highlighting the current and future state of shared decision making in gynecologic malignancies.

6:30 AM – 8:00 AM

Breakfast

6:30 AM – 12:00 PM

Registration Open

6:30 AM – 8:00 AM

Poster Presentations & Exhibit Hall Open

7:00 AM – 8:30 AM

ASCO Update

Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center

8:30 AM – 9:35 AM

General Session 5

Modertors: Dr. Katherine Fuh, Dr. Isabel Rodriguez

• 8:30 am – 8:45 am: AXL inhibition improves the therapeutic efficacy of trastuzumab in uterine serous cancers – presented by Anjali Walia, BS, University of California, San Francisco School of Medicine
• 8:46 am – 9:01 am: Consideration of PARPi therapy in patients with uterine leiomyosarcoma harboring homologous recombination deficiency repair mutations – presented by Elise Wilson, MD, UC San Diego Health
• 9:02 am – 9:17 am: Understanding the patient experience on and after mirvetuximab soravtansine in platinum-resistant ovarian cancer – presented by Alexandra Smick, MD, UCLA
• 9:18 am – 9:33 am: CCL23 reduces expression of CXCL10 in the Ovarian Cancer Tumor Microenvironment as a novel Mechanism of Immuno-Suppression – presented by Susan Lang, MD, Stanford University

9:35 AM – 9:55 AM

Break

9:55 AM – 11:30 AM

General Session 6

Moderators: Dr. Soledad Jorge, Dr. Malaika Amneus

• 9:55 am – 10:10 am: A Needs Assessment of Surgical Learning Gaps in Gynecologic Oncology Fellows at a Single Institution – presented by Yeon Woo Lee, MD, UCSF
• 10:11 am – 10:26 am: Peri-Operative Outcomes after Gravid Radical Hysterectomy for Treatment of Early-Stage Cervical Cancer – presented by Lydia Makepeace, MD, University of Texas at Southwestern Medical Center
• 10:27 am – 10:42 am: Novel approaches to managing placenta accreta spectrum: is there an advantage to a longer delay in hysterectomy timing? – presented by Karen Haney, MD, University of Texas Health Science Center
• 10:43 am – 10:58 am: Increasing Proportion of Adolescent and Young Adult (AYA) Patients Among Gynecologic Malignancies – presented by Christian Pino, MD, University of Southern California
• 10:59 am – 11:14 am: Exploring Sexual Distress and Surgical Decision-Making in Risk-reducing Gynecologic Surgery – presented by Alisha Othieno, MD, UCSF
• 11:15 am – 11:30 am: Older cervical cancer patients are inadequately screened prior to diagnosis: an opportunity for improvement – presented by Jaime Kiff, MD, University of Oklahoma Health Sciences Center

11:25 AM – 11:30 AM

Closing Remarks & WAGO 2025 Annual Meeting Location Announcement

WAGO 2025 Annual Meeting

Wednesday, June 18 –  Saturday, 21, 2025
Cheyenne Mountain Resort 
Colorado Springs, Colorado